This week, host Eve Young, economics correspondent for The Jerusalem Post, interviews Noam Solomon - CEO and co-founder at Immunai.

Immunai is a biotechnology company working to comprehensively map and decode the immune system with single-cell biology and AI to make new therapeutic discoveries, accelerate drug development, and improve patient outcomes. 

Noam will talk about how Immunai uses AI and machine learning to make medical advancements, and explain what machine learning is in laymans terms. He will also explain what kind of team is best suited to face the challenges of a complex, deep science problem like mapping human immunity.